SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Titan V Member Profile
 
Followed By 31
Posts 3,395
Boards Moderated 1
Alias Born 01/29/12
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2017 4:26:56 PM
Viking Therapeutics Announces Closing of Public Offering of Common Stock "PR Newswire (US)" - 12/11/2017 4:15:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/7/2017 4:40:46 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 6:04:54 AM
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock "PR Newswire (US)" - 12/6/2017 8:08:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/5/2017 4:30:49 PM
Viking Therapeutics Announces Proposed Public Offering of Common Stock "PR Newswire (US)" - 12/5/2017 4:18:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/28/2017 7:08:18 AM
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 11/28/2017 7:02:00 AM
Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeut... "GlobeNewswire Inc." - 11/20/2017 8:20:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 5:12:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:13:01 PM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 11/8/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 "PR Newswire (US)" - 11/1/2017 7:30:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/27/2017 6:02:23 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 10/26/2017 4:54:21 PM
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at... "PR Newswire (US)" - 10/24/2017 7:05:00 AM
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy ... "PR Newswire (US)" - 10/23/2017 7:05:00 AM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist